Clinical Trials Logo

Solid Tumors, Adult clinical trials

View clinical trials related to Solid Tumors, Adult.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05228015 Active, not recruiting - Solid Tumor Clinical Trials

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Start date: January 7, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally (PO) as monotherapy in subjects with advanced solid tumors with or without gene alterations in the Hippo pathway for whom there are no further treatment options known to confer clinical benefit. The study consists of two phases, an initial Dose Escalation phase followed by a Dose Expansion phase.

NCT ID: NCT05018273 Active, not recruiting - Solid Tumors, Adult Clinical Trials

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Start date: December 21, 2021
Phase: Phase 1
Study type: Interventional

A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination with atezolizumab, and to identify a RP2D for VB10.NEO in combination with atezolizumab, in patients with locally advanced and metastatic tumors that have progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care (SOC).